Dasabuvir Sodium Market

The Dasabuvir Sodium market is projected to grow at a CAGR of 4.9% from 2025 to 2035, supported by the persistent global burden of Hepatitis C Virus (HCV) and the continued integration of direct-acting antivirals (DAAs) into national treatment protocols. Dasabuvir Sodium, a non-nucleoside NS5B polymerase inhibitor, is mainly used in combination with other antivirals such as ombitasvir, paritaprevir, and ritonavir for treating HCV genotype 1 infection. The high potency, reduced treatment duration, and improved SVR (sustained virologic response) rates make it a key component in HCV treatment regimens.

Geographically, North America remains a key region due to the historical use of Dasabuvir-containing regimens and access to combination therapies. However, Asia-Pacific and Eastern Europe are experiencing growth due to the increasing awareness of hepatitis C screening and treatment, along with government-subsidized antiviral programs. Latin America and Middle East & Africa are witnessing expanding adoption due to WHO’s hepatitis elimination strategy and international funding support, which encourages access to established DAAs.

The Dasabuvir Sodium market is supported by collaborative efforts among pharmaceutical companies, global health alliances, and government agencies aiming to expand access to affordable HCV therapies. With efforts to optimize yield, reduce cost per kilogram, and scale up compliant production, manufacturers are positioning themselves to cater to both branded generic and clinical trial demands. Furthermore, a steady focus on regulatory filings, bioequivalence studies, and supply chain resilience is driving long-term growth. As the world continues to pursue the 2030 HCV elimination goals, Dasabuvir Sodium retains a strategic role in targeted therapeutic interventions.